Ouma Health Launches Ouma Connect, Giving Surrogacy Agencies a Clear View of Medical Clearance for Every Gestational-Carrier Candidate Abu Dhabi Invests In The Next Generation Of Musical Talent With A New Dedicated Institution For The Youth Orchestra Abu Dhabi Canton Fair Expands Human-Centered Approach Through Shared Experiences, Culture and Dialogue Amflow Announces Sales Availability for Two of Its Most Anticipated Models ASICS Opens Its First Industry-Academia R&D Lab for Running Innovation with the University of Michigan Clarins Lights Up the Austin Skyline with an Immersive Celebration of Skin Longevity Monster Energy and Call of Duty® Take Over Cosm Los Angeles for Immersive Modern Warfare® 4 Launch Celebration Come Back to Firefox: Mozilla launches its most ambitious campaign yet to bring people back to the independent alternative to big tech browsers Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine Ouma Health Launches Ouma Connect, Giving Surrogacy Agencies a Clear View of Medical Clearance for Every Gestational-Carrier Candidate Abu Dhabi Invests In The Next Generation Of Musical Talent With A New Dedicated Institution For The Youth Orchestra Abu Dhabi Canton Fair Expands Human-Centered Approach Through Shared Experiences, Culture and Dialogue Amflow Announces Sales Availability for Two of Its Most Anticipated Models ASICS Opens Its First Industry-Academia R&D Lab for Running Innovation with the University of Michigan Clarins Lights Up the Austin Skyline with an Immersive Celebration of Skin Longevity Monster Energy and Call of Duty® Take Over Cosm Los Angeles for Immersive Modern Warfare® 4 Launch Celebration Come Back to Firefox: Mozilla launches its most ambitious campaign yet to bring people back to the independent alternative to big tech browsers Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine